1. [The correlation of asymmetrical dimethylarginine level and oxidative stress to the onset of Alzheimer's disease].
- Author
-
Chen M, Jiang P, Lü J, Xiang ZH, and Jiao BH
- Subjects
- Aged, Amyloid beta-Peptides cerebrospinal fluid, Arginine cerebrospinal fluid, Female, Humans, Male, Malondialdehyde cerebrospinal fluid, Middle Aged, Nitric Oxide cerebrospinal fluid, Nitric Oxide Synthase Type II cerebrospinal fluid, Peptide Fragments cerebrospinal fluid, Peroxynitrous Acid cerebrospinal fluid, Reactive Oxygen Species cerebrospinal fluid, Tyrosine analogs & derivatives, Tyrosine cerebrospinal fluid, Alzheimer Disease cerebrospinal fluid, Arginine analogs & derivatives, Oxidative Stress
- Abstract
This study is to investigate the influence and mechanism of action of asymmetrical dimethylarginine (ADMA) and the induced oxidative stress level on Alzheimer's disease (AD) incidence. ADMA concentration, nitric oxide, Abeta(40)/Abeta(42) ratio, inducible NO synthase (iNOS) activity and the concentrations of the induced free radicals including malondialdehyde (MDA), 3-nitrotyrosine (3-NT) and peroxynitrite (ONOO-) in the cerebrospinal fluid (CSF) from 34 neurologically normal controls and 37 AD patients were quantitatively determined and statistically compared. The results showed that the ADMA concentration significantly decreased in AD patients, and it showed negative correlation with the NO, iNOS activity, and showed positive correlation with MMSE score. ADMA concentration was negatively correlated with Abeta(40)/Abeta(42) ratio (P<0.01) with the observation that Abeta(40)/Abeta(42) ratio increased while ADMA level decreased in CSF in AD patients. The concentration levels of MDA, 3-NT and ROS significantly increased compared with the control with all the P values less than 0.05. These findings suggested that the ADMA disorder and the oxidative damage effect of the induced free radicals in CSF of AD patients are an important mechanism of AD incidence, and their joint regulation may provide new idea for the prevention and clinical treatment of AD.
- Published
- 2010